The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial

• Published in: BMC medicine Vol. 21; no. 1; pp. 94 - 12
• Main Authors: Tang, Lin-Quan, Li, Xiao-Yun, Li, Zhi-Ming, Liu, Zhi-Gang, Lin, Miao-Zhen, Zhou, Huan, Yu, Qi-Wen, Zhou, Jian, Zhao, Chong, Chen, Ze-Bin, Wang, Xi-Cheng, Peng, Jia-Yu, Chen, Qiu-Yan, Fang, Wen-Feng, Yang, Yun-Peng, Zhang, Bei, Xia, Liang-Ping, Hu, Pi-Li, Hu, Wei-Han, Li, Yi-Jie, Mai, Hai-Qiang, Cai, Xiu-Yu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.03.2023; BioMed Central; BMC
• Subjects: Anemia; Apatinib; Apoptosis; Cancer; Cancer therapies; Capecitabine; Capecitabine - adverse effects; Chemotherapy; Clinical trials; Disease control; Dosage and administration; Drug dosages; Drug therapy; Drug withdrawal; Effectiveness; Enrollments; Evaluation; Head & neck cancer; Humans; Hypertension; Kinases; Magnetic resonance imaging; Medical prognosis; Metastases; Metastasis; Methods; Mucositis; Nasopharyngeal cancer; Nasopharyngeal carcinoma; Nasopharyngeal Carcinoma - drug therapy; Nasopharyngeal Neoplasms - drug therapy; Platinum; Prospective Studies; Protein-tyrosine kinase; Proteinuria; Radiation therapy; Relapse; Safety; Solid tumors; Survival; Throat cancer; Toxicity; Tumors; Tyrosine; Tyrosine kinase inhibitor; Vascular endothelial growth factor; China; Apatinib; Nasopharyngeal carcinoma; Tyrosine kinase inhibitor

Previous studies have shown that monotherapy with apatinib, an oral tyrosine kinase inhibitor, has promising efficacy for treating recurrent or metastatic (RM) nasopharyngeal carcinoma (NPC) patients. In this study, we aimed to assess the efficacy and safety of apatinib combined with capecitabine as...